Lipocine Total Current Liabilities Over Time
| LPCN Stock | USD 5.00 0.29 6.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lipocine Performance and Lipocine Correlation. Lipocine |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share 0.903 | Quarterly Revenue Growth 137.519 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare Lipocine and related stocks such as Sigilon Therapeutics, Reviva Pharmaceuticals, and ZyVersa Therapeutics Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 6.1 M | 6.1 M | 6.1 M | 6.1 M | 6.1 M | 6.1 M | 6.1 M | 6.1 M | 6.1 M | 6.8 M | 1.3 M | 2.3 M | 6 M | 17.2 M | 18 M |
| ZVSA | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 13.6 M | 8.2 M | 10.2 M | 10.9 M |
| UNCY | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 903 K | 2.9 M | 2.1 M | 3.3 M | 17.5 M | 18.4 M |
| CKPT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 M | 3.7 M | 6.4 M | 13.1 M | 8.1 M | 7.2 M | 26 M | 32.8 M | 18.4 M | 12.9 M |
| MBIO | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 3.2 M | 3.6 M | 5.6 M | 7.8 M | 9.5 M | 10.8 M | 15.1 M | 15.4 M | 9.2 M |
| KOD | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 9.2 M | 4.8 M | 11.7 M | 31.4 M | 64.7 M | 52.5 M | 41.7 M | 30 M |
| ARDX | 16.8 M | 16.8 M | 16.8 M | 17.1 M | 5.6 M | 7.7 M | 19.2 M | 17.9 M | 17.7 M | 22.2 M | 28.4 M | 57.5 M | 74.6 M | 50.4 M | 30.7 M |
| ZURA | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 39 K | 14.8 M | 20.3 M | 12.9 M |
| HEPA | 227.2 K | 227.2 K | 227.2 K | 458.7 K | 458.7 K | 1.9 M | 5.1 M | 2.9 M | 2.8 M | 1.6 M | 4.7 M | 8.2 M | 7.9 M | 5.3 M | 3.8 M |
| VSTM | 368 K | 3.1 M | 2.4 M | 7.8 M | 9.2 M | 10 M | 11 M | 17.1 M | 37.1 M | 29.9 M | 17.1 M | 18.6 M | 21.7 M | 26.4 M | 16.6 M |
| RVPHW | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 1.3 M | 2.3 M | 6 M | 17.2 M | 18 M |
| EYEN | 419.8 K | 419.8 K | 419.8 K | 419.8 K | 419.8 K | 419.8 K | 423.7 K | 552.6 K | 3.1 M | 2.9 M | 18.2 M | 11.2 M | 4.5 M | 9.5 M | 6.2 M |
| CGTX | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.2 M | 7.9 M | 7.8 M | 10.2 M | 7.2 M |
| RNAZ | 117.7 K | 117.7 K | 117.7 K | 117.7 K | 117.7 K | 117.7 K | 117.7 K | 117.7 K | 117.7 K | 62.9 K | 404.9 K | 2.5 M | 4.3 M | 3.5 M | 2 M |
Lipocine and related stocks such as Sigilon Therapeutics, Reviva Pharmaceuticals, and ZyVersa Therapeutics Total Current Liabilities description
Total Current Liabilities is an item on Lipocine balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lipocine are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
Check out Lipocine Performance and Lipocine Correlation. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Lipocine technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.